vaccin
achiev
remark
success
control
childhood
viral
diseas
control
emerg
infect
howev
vaccin
need
deliv
older
individu
unlik
infant
probabl
prior
infect
vaccin
relat
virus
thu
crossreact
antibodi
vaccin
whether
crossreact
antibodi
impact
live
attenu
vaccin
efficaci
unclear
use
openlabel
random
trial
design
show
subject
specif
rang
crossreact
antibodi
titr
prior
inactiv
japanes
enceph
vaccin
enhanc
yellow
fever
yf
immunogen
upon
yf
vaccin
enhanc
titr
crossreact
antibodi
prolong
yf
vaccin
viraemia
provok
greater
proinflammatori
respons
induc
adhes
molecul
intrins
activ
fcreceptor
signal
pathway
name
immun
semaphorin
facilit
immun
cell
interact
traffick
find
clinic
demonstr
antibodyenhanc
infect
suggest
vaccin
efficaci
could
improv
exploit
crossreact
antibodi
clinic
trial
featur
investig
crossreact
antibodi
affect
live
attenu
vaccin
examin
open
v
iral
infect
spread
rapidli
transcontinent
becom
increasingli
preval
first
year
centuri
alon
alreadi
wit
pandem
spread
sever
acut
respiratori
syndrom
sar
coronaviru
swine
origin
influenza
ebola
zika
virus
caus
global
health
emerg
strategi
employ
prevent
viral
spread
vaccinationespeci
live
vaccinesha
undoubtedli
remark
track
record
vaccin
erad
smallpox
elimin
polio
part
world
recent
clusterrandom
trial
demonstr
ring
vaccin
contact
ebola
case
virtual
elimin
secondari
spread
viru
measur
abl
effect
prevent
spread
virus
suscept
popul
thu
top
research
prioriti
develop
immunogen
candid
vaccin
frequent
evalu
anim
human
immunolog
naiv
pathogen
interest
reason
approach
vaccin
like
given
infant
young
children
prevent
childhood
diseas
emerg
virus
howev
vaccin
deliv
children
adult
mani
probabl
prior
infect
vaccin
crossreact
virus
antigen
relat
vaccin
strain
inde
endem
human
coronavirus
global
impli
sar
middl
east
respiratori
syndrom
mer
coronaviru
vaccin
must
effect
despit
presenc
anticoronaviru
antibodi
similarli
control
yellow
fever
vaccin
even
zika
viru
vaccin
becom
avail
probabl
conduct
popul
high
preval
dengu
antibodi
virus
transmit
mosquito
vector
howev
whether
crossreact
antibodi
modifi
live
vaccin
outcom
remain
unclear
report
suggest
crossreact
antibodi
reduc
vaccin
efficaci
contrast
recent
phase
trial
chimaer
dengu
vaccin
show
subject
prior
flaviviru
infect
experienc
significantli
better
efficaci
individu
immunolog
naiv
flavivirus
efficaci
live
attenu
viru
lav
vaccin
may
influenc
antibodydepend
enhanc
ade
infect
popular
hypothesi
explain
increas
risk
sever
diseas
upon
secondari
dengu
viru
infect
hypothesi
posit
crossreact
subneutr
level
antibodi
develop
prior
infect
heterolog
antigen
relat
viru
enhanc
viral
entri
target
cell
via
fc
gamma
receptor
thu
possibl
crossreact
antibodi
augment
immunogen
enhanc
lav
infect
antigen
present
cell
apc
trigger
host
respons
intrins
activ
signal
inde
demonstr
increas
immunogen
infect
activ
pathway
intrins
activ
would
also
authent
ade
hypothesi
clinic
demonstr
experiment
system
label
random
clinic
trial
effect
sequenti
vaccin
two
flavivir
vaccin
inactiv
japanes
enceph
je
vaccin
live
attenu
yellow
fever
yf
vaccin
licens
flavivir
vaccin
select
safeti
profil
known
gener
crossreact
antibodi
bind
flavivirus
includ
dengu
west
nile
zika
virus
total
healthi
volunt
test
neg
antidengu
immunoglobulin
igg
enzymelink
immunosorb
assay
elisa
random
upon
receipt
written
inform
consent
receiv
je
follow
yf
vaccin
yf
vaccin
alon
fig
supplementari
tabl
achiev
gradient
crossreact
antibodi
yf
vaccin
subdivid
subject
three
group
base
time
interv
je
yf
vaccin
one
group
four
group
nine
month
group
vaccin
group
subject
serv
control
yf
vaccin
administ
fig
supplementari
tabl
advers
event
ae
follow
je
yf
vaccin
differ
among
differ
group
supplementari
tabl
two
subject
group
suspect
dengu
thu
exclud
analysi
level
je
antibodi
significantli
reduc
increas
amount
time
postcomplet
twodos
vaccin
schedul
gener
gradient
je
antibodi
point
yf
vaccin
fig
notabl
group
subject
differ
je
antibodi
compar
group
provid
broad
rang
je
antibodi
titr
cover
observ
group
allow
us
studi
effect
crossreact
je
antibodi
subsequ
yf
vaccin
primari
endpoint
yf
neutral
antibodi
titr
one
month
post
yf
vaccin
exploratori
endpoint
includ
yf
vaccin
viraemia
system
biolog
profil
host
respons
vaccin
antibodyenhanc
yf
infect
result
prolong
viraemia
signific
differ
one
month
yf
neutral
antibodi
titr
observ
differ
group
supplementari
fig
yf
neutral
antibodi
titr
one
month
post
yf
vaccin
analys
je
antibodi
titr
day
yf
vaccin
invert
u
trend
fig
supplementari
fig
fit
second
polynomi
function
p
observ
trend
similar
vitro
studi
demonstr
ade
dengu
viru
infect
monocyt
macrophag
dendrit
cell
dc
yf
neutral
antibodi
titr
independ
age
bodi
mass
index
gender
ethnic
supplementari
fig
also
correl
yf
je
antibodi
one
month
post
yf
vaccin
suggest
higher
yf
neutral
antibodi
respons
due
boost
je
memori
respons
fig
supplementari
fig
instead
yf
neutral
antibodi
titr
correl
directli
magnitud
preyf
vaccin
sera
enhanc
infect
monocyt
cell
vitro
fig
contrast
control
group
correl
observ
fig
collect
find
suggest
crossreact
je
antibodi
bind
yf
vaccin
enhanc
infect
apc
next
measur
je
vaccin
affect
yf
vaccin
viraemia
day
postyf
vaccin
subject
treatment
group
group
divid
without
enhanc
genom
copi
log
per
yf
titr
log
figur
crossreact
antibodi
enhanc
yf
vaccin
infect
produc
prolong
viraemia
improv
immunogen
b
correl
antij
day
antij
month
b
versu
antiyf
month
specif
antibodi
titr
group
n
measur
prnt
dot
line
indic
confid
interv
mean
titr
group
enhanc
group
defin
subject
titr
greater
confid
interv
group
c
preyf
immun
sera
treatment
group
group
n
c
control
group
n
dilut
incub
infect
monocyt
plaqu
titr
repres
prevaccin
serum
mediat
infect
correl
logtransform
yf
antibodi
titr
month
eg
yf
rna
level
day
yf
vaccin
group
subject
n
e
nonenhanc
group
n
f
enhanc
group
n
g
h
j
yf
rna
level
across
differ
group
day
h
day
j
postyf
vaccin
error
bar
indic
standard
error
mean
k
correl
logtransform
yf
antibodi
titr
month
logtransform
yf
rna
level
observ
day
day
k
n
p
p
pair
ttest
eg
unpair
ttest
h
j
neutral
antibodi
respons
yf
base
whether
neutral
antibodi
titr
greater
lower
upper
limit
confid
interv
mean
titr
control
group
respect
fig
consist
previou
report
increas
yf
vaccin
viraemia
observ
subject
day
day
declin
significantli
day
control
group
fig
major
subject
nonenhanc
group
also
display
reduc
viraemia
level
day
day
fig
contrast
major
subject
enhanc
group
show
sustain
increas
viraemia
level
day
fig
compar
viraemia
level
day
alon
mean
viraemia
control
group
subject
higher
prior
je
vaccin
fig
howev
day
viraemia
level
show
signific
correl
eventu
yf
antibodi
titr
fig
viraemia
level
day
highest
enhanc
group
fig
correl
eventu
yf
antibodi
titr
fig
collect
result
suggest
crossreact
antibodi
improv
vaccin
immunogen
increas
durat
viraemia
clinic
sever
ae
observ
cohort
moreov
signific
differ
total
ae
observ
differ
group
yf
respond
supplementari
tabl
indic
prolong
viraemia
mediat
crossreact
antibodi
affect
occurr
sever
ae
antibodyenhanc
yf
vaccin
increas
product
proinflammatori
lipid
metabolit
gain
insight
host
respons
yf
vaccin
alter
crossreact
antibodi
adopt
system
biolog
nontarget
approach
examin
metabolom
gene
express
cytokinechemokin
concentr
peripher
blood
first
global
metabolom
investig
detail
chemic
fingerprint
left
behind
cellular
process
identifi
significantli
differ
featur
enrich
metabol
pathway
includ
aminoacylrnatrna
biosynthesi
linol
acid
suggest
increas
translat
arachidon
acid
synthesi
respect
act
major
contributori
factor
enhanc
yf
immunogen
supplementari
tabl
inde
followup
target
analysi
identifi
proinflammatori
lipid
specif
arachidon
acid
linol
acid
metabolit
byproduct
acid
significantli
elev
enhanc
group
fig
c
e
posit
correl
yf
antibodi
titr
fig
f
find
suggest
yf
vaccin
presenc
enhanc
level
crossreact
antibodi
result
greater
proinflammatori
respons
antibodyenhanc
yf
vaccin
lead
increas
semaphorin
express
glean
enhanc
antibodi
alter
gene
express
respons
yf
vaccin
perform
transcript
profil
peripher
blood
mononuclear
cell
pbmc
subject
geneset
enrich
analysi
gsea
use
determin
enrich
molecular
pathway
although
chang
gene
express
observ
day
gene
express
chang
occur
day
consist
report
pathway
associ
interferon
innat
antivir
respons
posit
enrich
treatment
control
group
supplementari
fig
furthermor
gene
express
previous
shown
associ
better
yf
antibodi
respons
also
posit
correl
yf
titr
control
group
supplementari
fig
correl
howev
signific
subject
prior
je
vaccin
supplementari
fig
expect
gene
pathway
significantli
enrich
prior
je
vaccin
compar
control
group
mostli
relat
pathway
protein
kinas
b
akt
casita
blineag
lymphoma
cbl
extracellular
signalregul
kinas
erk
signal
supplementari
fig
b
subject
enhanc
group
howev
show
enrich
tcellrel
pathway
specif
signal
interleukin
receptor
signal
pathway
compar
nonenhanc
group
control
group
fig
interestingli
semaphorinrel
pathway
known
import
role
regul
immun
cell
respons
also
significantli
enrich
enhanc
group
fig
supplementari
fig
inde
gene
semaphorinrel
pathway
posit
correl
yf
antibodi
titr
along
interleukin
signal
gene
subject
prior
je
vaccin
fig
contrast
signific
correl
observ
control
group
valid
gsea
hit
fig
use
quantit
realtim
polymeras
chain
reaction
qpcr
produc
similarli
signific
correl
transcript
semaphorinrel
gene
day
postyf
vaccin
yf
antibodi
respons
supplementari
fig
similarli
independ
verif
immun
semaphorin
anoth
ten
trial
subject
use
qpcr
produc
similar
find
supplementari
fig
taken
collect
conclud
semaphorin
correspond
receptor
significantli
posit
correl
yf
antibodi
respons
fig
semaphorin
first
identifi
serv
axon
guidanc
factor
neuron
develop
subsequ
subset
semaphorin
discov
play
import
role
regul
immun
cell
especi
apc
cell
interact
well
cellular
traffick
consist
gene
express
find
serum
cytokin
measur
identifi
two
cytokin
significantli
correl
yf
neutral
antibodi
titr
regul
cell
expans
activ
supplementari
tabl
first
plateletderiv
growth
factor
isoformbb
pdgfbb
affect
cell
expans
significantli
reduc
control
nonenhanc
group
day
rel
day
enhanc
group
supplementari
fig
b
second
reduc
level
vascular
endotheli
growth
factord
vegfd
inhibit
cell
prolifer
activ
observ
enhanc
group
postyf
vaccin
control
nonenhanc
group
supplementari
fig
vegfd
level
also
neg
correl
yf
antibodi
titr
supplementari
fig
cytokin
data
thu
support
gene
express
find
collect
data
suggest
yf
vaccin
presenc
enhanc
level
crossreact
antibodi
induc
express
gene
cytokin
augment
cell
respons
increas
semaphorin
express
mediat
activ
signal
fact
semaphorin
gene
upregul
upon
yf
vaccin
individu
prior
je
vaccin
intrigu
may
indic
signal
pathway
intrins
activ
trigger
ade
test
possibl
known
express
monocyt
measur
express
monocyt
follow
inocul
viru
opson
enhanc
concentr
mousehuman
chimaer
antibodi
antibodi
bind
conserv
fusion
loop
flavivirus
includ
viru
supplementari
fig
immun
complex
form
supplementari
fig
result
upregul
mrna
supplementari
fig
protein
level
fig
supplementari
fig
h
postinfect
inocul
alon
chang
express
similarli
opson
preyf
vaccin
serum
enhanc
group
subject
supplementari
fig
upregul
express
primari
monocyt
fig
significantli
reduc
activ
block
monoclon
antibodi
fig
furthermor
crosslink
activ
fcreceptor
alon
monoclon
antibodi
result
signific
upregul
fig
primari
monocyt
fig
togeth
result
indic
activ
signal
directli
induc
semaphorin
express
monocyt
cell
dc
central
initi
primari
immun
respons
investig
express
semaphorin
dc
colig
opson
preyf
vaccin
serum
enhanc
group
increas
infect
monocytederiv
dc
supplementari
fig
crosslink
result
signific
upregul
fig
fig
consist
previou
report
demonstr
dc
express
low
level
ref
collect
result
indic
engag
activ
upregul
semaphorin
antigenpres
cell
lead
improv
cellmedi
respons
activ
signal
lead
increas
activ
matur
express
semaphorin
dendrit
cell
vivo
vitro
experi
shown
signal
induc
semaphorin
express
prior
je
immun
may
also
induc
adapt
immun
respons
alter
semaphorin
express
independ
activ
exclud
possibl
investig
vivo
effect
crossreact
antibodi
yf
vaccin
absenc
crossreact
cellular
immun
mice
first
immun
inactiv
je
vaccin
day
igg
fraction
purifi
mous
sera
transfer
immunolog
naiv
anim
thereaft
yf
vaccin
administ
mice
drain
lymph
node
dln
isol
h
postvaccin
assess
migrat
activ
dc
fig
gate
strategi
identifi
dc
shown
supplementari
fig
increas
concentr
crossreact
je
igg
antibodi
total
dc
fig
activ
dc
fig
dln
increas
dosedepend
manner
consist
vitro
observ
low
concentr
je
crossreact
antibodi
result
increas
percentag
dc
fig
e
higher
mean
fluoresc
intens
mfi
fig
contrast
differ
mfi
observ
across
total
cell
dln
mice
given
preimmun
sera
supplemntari
fig
suggest
yf
immun
complex
induc
dc
fig
overal
vivo
result
indic
enhanc
level
crossreact
antibodi
alon
increas
dc
migrat
activ
well
semaphorin
upregul
contribut
enhanc
immunogen
clinic
trial
experiment
find
collect
indic
crossreact
antibodi
within
limit
rang
enhanc
immunogen
lav
augment
infect
activ
host
respons
downstream
activ
also
authent
ade
viral
infect
clinic
inde
small
minor
dengu
patient
secondarili
infect
crossreact
serotyp
dengu
viru
develop
sever
diseas
immunogen
enhanc
observ
within
restrict
rang
preexist
je
antibodi
titr
explain
stoichiometri
requir
optim
colig
activ
low
titr
antibodi
could
suboptim
activ
colig
wherea
high
titr
crossreact
antibodi
could
aggreg
yf
vaccin
instead
colig
inhibitori
reduc
uptak
vaccin
apc
ref
ade
infect
led
prolong
viraemia
signal
could
least
part
result
upregul
inflammatori
metabolit
interpret
consist
previou
report
show
immun
complex
upregul
metabolit
result
increas
phagocytosi
improv
immun
respons
addit
gene
pathway
cytokin
known
regul
cell
activ
differenti
upregul
although
demonstr
actual
improv
cell
function
need
shown
separ
studi
observ
could
potenti
explain
individu
preexposur
flaviviru
infect
demonstr
improv
efficaci
chimaer
yfdengu
viru
vaccin
compar
immunolog
naiv
individu
associ
immun
semaphorin
express
enhanc
immunogen
interest
possibl
semaphorin
alter
effici
yf
vaccin
infect
apc
henc
immunogen
howev
given
known
function
set
gene
regul
immun
cell
interact
traffick
like
induct
activ
augment
apc
cell
crosstalk
enhanc
immunogen
exact
mechan
action
semaphorin
regul
immunogen
need
investig
multipl
factor
propos
influenc
vaccin
efficaci
includ
host
genet
human
microbiom
environment
influenc
studi
highlight
vaccin
efficaci
posit
influenc
past
exposur
heterolog
virus
provid
crossreact
antibodi
titr
optim
lav
enhanc
suggest
possibl
ade
could
exploit
deliv
lav
overcom
key
limit
vaccin
lav
report
previous
trigger
extens
innat
immun
respons
soon
vaccin
although
respons
need
stimul
adapt
immun
respons
lav
may
also
rapidli
clear
vaccin
therebi
limit
window
avail
adapt
immun
respons
expos
antigen
inde
find
viraemia
level
day
day
post
yf
vaccin
correl
eventu
yf
neutral
antibodi
titr
indic
durat
lav
infect
influenc
immunogen
surprisingli
therefor
even
highli
potent
lav
measl
polio
requir
booster
sustain
longterm
immun
typic
aris
follow
natur
wildtyp
viral
infect
improv
immunogen
live
attenu
yf
vaccin
enhanc
titr
crossreact
antibodi
thu
suggest
approach
overcom
shortliv
immun
vaccin
could
also
lead
reduc
need
multipl
dose
regim
achiev
adequ
neutral
antibodi
titr
suffici
protect
immun
determin
vaccin
dose
achiev
antibodyantigen
stoichiometri
optim
activ
colig
enhanc
lav
infect
immunogen
could
thu
pragmat
approach
achiev
longerlast
vaccin
efficaci
conclus
shown
crossreact
antibodi
enhanc
lav
immunogen
infect
activ
host
respons
includ
activ
intrins
pathway
improv
innat
adapt
immun
crosstalk
supplementari
fig
strategi
exploit
ade
improv
vaccin
immunogen
thu
explor
onset
vaccin
design
develop
ethic
approv
trial
approv
studi
obtain
singhealth
centralis
institut
review
board
regist
clinicaltrialsgov
registr
particip
gave
written
inform
consent
clinic
trial
design
detail
studi
design
describ
previous
briefli
healthi
adult
prescreen
neg
antidengu
antibodi
panbio
dengu
igg
aler
enrol
receiv
inform
consent
subject
random
two
arm
subject
treatment
arm
group
receiv
two
dose
inactiv
je
vaccin
ixiaro
novarti
singapor
pte
ltd
subject
control
arm
group
receiv
je
vaccin
treatment
arm
subdivid
three
group
yf
vaccin
stamaril
sanofi
pasteur
sa
administ
differ
time
interv
postj
vaccin
month
group
month
group
month
group
control
group
receiv
yf
vaccin
serum
extract
day
immedi
yf
vaccin
well
day
month
postyf
vaccin
primari
endpoint
trial
yf
antibodi
titr
month
postyf
vaccin
throughout
entir
trial
period
subject
document
local
system
symptom
experienc
je
andor
yf
vaccin
includ
local
system
symptom
cell
virus
vero
purchas
atcc
authent
flow
cytometri
cell
line
test
mycoplasma
contamin
viru
isol
stamaril
passag
vero
cell
je
cultur
vero
cell
virus
store
use
infecti
titr
determin
plaqu
assay
plaqu
reduct
neutral
test
plaqu
reduct
neutral
test
prnt
perform
cell
serial
twofold
dilut
serum
rpmi
mainten
medium
mm
incub
pfu
je
pfu
viru
equal
volum
h
ad
per
well
h
incub
medium
aspir
cell
overlaid
carboxymethyl
cellulos
mm
day
cell
fix
formaldehyd
stain
crystal
violet
valu
determin
use
sigmoid
doserespons
curv
fit
report
reciproc
valu
antibodydepend
infect
predos
serum
dilut
titrat
incub
pfu
per
h
ad
cell
multipl
infect
moi
day
incub
result
viral
titr
quantifi
plaqu
assay
previous
describ
viraemia
assess
qpcr
rna
sera
extract
use
viral
rna
isol
kit
qiagen
follow
cdna
synthesi
biorad
realtim
qpcr
roch
accord
manufactur
protocol
primer
use
previous
report
rna
copi
number
standard
synthes
amplifi
amplicon
ecori
xbai
flank
site
clone
origen
rna
copi
number
calcul
previous
describ
limit
detect
determin
genom
copi
liquid
chromatographytandem
mass
spectrometri
lcmsm
profil
sera
patient
collect
day
collect
metabolom
analysi
untarget
metabolom
perform
previous
describ
modif
supernat
fraction
sampl
prepar
step
analys
use
agil
ultrahigh
pressur
liquid
chromatographi
system
equip
qtof
mass
detector
column
use
separ
agil
rapid
resolut
ht
zorbax
mm
mm
agil
technolog
gradient
elut
involv
mobil
phase
consist
formic
acid
water
b
formic
acid
methanol
initi
condit
set
b
min
linear
gradient
b
appli
follow
min
gradient
b
held
min
return
start
condit
min
electrospray
ioniz
mass
spectra
acquir
posit
ion
mode
mass
data
collect
mz
rate
two
scan
per
second
ion
spray
voltag
set
v
heat
capillari
temperatur
maintain
dri
ga
nebul
nitrogen
ga
flow
rate
l
min
psi
respect
two
refer
mass
continu
infus
system
allow
constant
mass
correct
run
mz
c
h
n
mz
c
h
n
p
f
target
lipidom
analysi
reversedphas
liquid
chromatographi
rplc
ms
analysi
perform
agil
ultra
pressur
liquid
chromatographi
devic
uplc
coupl
electrospray
ioniz
ifunnel
technolog
devic
tripl
quadrupol
mass
spectromet
qqq
agil
technolog
chromatograph
separ
extract
eicosanoid
achiev
use
ht
zorbax
column
mm
agil
technolog
flow
rate
ml
min
initi
condit
set
b
min
linear
gradient
b
appli
follow
min
gradient
b
held
min
return
start
condit
min
use
solvent
aqueou
acet
acid
b
volvol
acetonitril
isopropanol
electrospray
ioniz
perform
neg
mode
follow
sourc
paramet
dri
ga
n
temperatur
flow
rate
l
min
nebul
ga
pressur
psi
sheath
ga
temperatur
flow
rate
l
min
capillari
voltag
v
nozzl
voltag
v
eicosanoid
quantifi
multipl
reaction
monitor
mrm
mode
data
acquisit
process
global
target
analys
perform
use
masshunt
softwar
agil
technolog
cytokin
profil
sera
assay
cytokin
chemokin
growth
factor
supplementari
tabl
use
multiplex
suspens
bead
immunoassay
ebiosci
accord
manufactur
protocol
sampl
random
run
duplic
data
analysi
experiment
data
carri
use
fiveparamet
logist
regress
model
bioplex
system
biorad
calibr
valid
perform
run
monthli
basi
respect
gene
express
analysi
whole
blood
extract
store
tempu
blood
rna
tube
respect
time
point
rna
isol
proceed
accord
manufactur
protocol
microarray
perform
dukenu
genom
biolog
core
facil
crna
hybrid
illumina
human
beadchip
accord
manufactur
instruct
data
analysi
perform
use
partek
softwar
significantli
enrich
pathway
correl
pathway
analys
gsea
reactom
databas
use
nomin
p
valu
cutoff
microarray
data
avail
arrayexpress
databas
wwwebiacukarrayexpress
access
microarray
valid
cdna
synthesi
perform
iscript
cdna
kit
biorad
realtim
qpcr
perform
accord
manufactur
protocol
roch
sybr
green
primer
use
valid
obtain
origen
gener
primari
monocyt
dc
primari
monocyt
isol
princip
investig
cultur
previous
describ
monocytederiv
dc
gener
cultur
primari
monocyt
ng
ml
granulocyt
macrophagecoloni
stimul
factor
gmcsf
ng
ml
day
flow
cytometri
analysi
confirm
treat
monocyt
express
dc
marker
includ
dcsign
supplementari
fig
bind
chimaer
humanmous
construct
previous
describ
briefli
cdna
encod
variabl
region
synthes
hybridoma
cell
use
templat
amplifi
heavyand
lightchain
variabl
region
human
constant
region
express
vector
chimaer
antibodi
express
freestyl
express
system
invitrogen
assess
bind
elisa
perform
previous
describ
crosslink
block
cell
cell
ml
incub
ml
either
ebiosci
stem
cell
biolog
h
agit
everi
min
antibodi
use
respect
isotoyp
control
cell
wash
mm
block
studi
cell
incub
opson
prevaccin
serum
enhanc
group
h
crosslink
experi
antimous
igg
ad
incub
h
thereaft
cell
collect
qpcr
western
blot
analysi
gene
transcript
level
qpcr
assess
gene
cell
wash
pb
follow
rna
extract
use
rneasi
kit
cdna
synthesi
realtim
qpcr
accord
manufactur
protocol
primer
use
gene
obtain
origen
immunofluoresc
infect
subject
cytospin
min
wash
pb
rabbit
abcam
ad
incub
overnight
wash
pb
antirabbit
ad
incub
room
temperatur
h
thereaft
mowiol
dapi
ad
view
zeiss
confoc
microscop
western
blot
western
blot
perform
analys
previous
describ
use
rabbit
abcam
mous
gapdh
abcam
primari
antibodi
horseradish
peroxidaseconjug
antirabbit
abcam
antimous
dako
respect
secondari
antibodi
mous
model
assess
effect
crossreact
antibodi
mice
obtain
invivo
singapor
hous
dukenu
vivarium
durat
experi
protocol
approv
singhealth
iacuc
mice
vaccin
intraperiton
inject
human
inactiv
je
vaccin
ixiaro
day
mice
kill
blood
collect
intracardiac
punctur
igg
purifi
pool
mous
serum
use
nab
protein
ag
spin
kit
thermoscientif
purifi
igg
quantit
nanodrop
transfer
naiv
mice
three
differ
concentr
intraperiton
inject
control
group
given
salin
alon
h
group
challeng
stamaril
ui
per
mous
subcutan
rear
footpad
lymph
node
n
independ
lymph
node
per
group
isol
addit
h
singl
cell
suspens
prepar
use
nylon
cell
strainer
falcon
treatment
min
collagenas
sigma
tissu
cultur
incub
cell
block
pb
contain
bovin
serum
albumin
bsa
gibco
determin
number
activ
dc
level
cell
stain
antibodi
blue
thermoscientif
bd
bioscienc
bd
bioscienc
abcam
buffer
consist
pb
contain
bsa
wash
pb
antirabbit
use
secondari
stain
wash
cell
fix
paraformaldehyd
data
acquir
use
fortessa
flow
cytomet
bd
bioscienc
analys
prepar
public
use
flowjo
prism
softwar
femal
mice
week
old
begin
experi
sampl
size
calcul
perform
advanc
random
blind
procedur
use
data
avail
microarray
data
deposit
arrayexpress
databas
wwwebiacukarrayexpress
access
